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MetabolismThe type II interleukin-4 receptor (IL4R) is expressed in human breast cancer, and inmurinemodels thereof. It is
activated by interleukin-4 (IL4), a cytokine produced predominantly by immune cells. Previously, we showed
that expression of IL4Rα, a signaling component of IL4R, mediates enhancedmetastatic growth through promo-
tion of tumor cell survival and proliferation. In lymphocytes, these processes are supported by increased glucose
and glutaminemetabolism, and B lymphocyte survival is dependent upon IL4/IL4R-induced glucosemetabolism.
However, it is unknown whether IL4R-mediated metabolic reprogramming could support tumor growth. Here,
we show that IL4Rα expression increases proliferation thus enhancing primary mammary tumor growth. In
vitro, IL4-enhanced glucose consumption and lactate production in 4T1 cells was mediated by IL4Rα. Expression
of the glucose transporter GLUT1 increased in response to IL4 in vitro, and enhanced GLUT1 expression was
associated with the presence of IL4Rα in 4T1 mammary tumors in vivo. Although IL4 treatment did not induce
changes in glucose metabolism in MDA-MB-231 human breast cancer cells, it increased expression of the main
glutamine transporter, ASCT2, and enhanced glutamine consumption in both MDA-MB-231 and 4T1 cells. Phar-
macologic inhibition of glutamine metabolism with compound 968 blocked IL4/IL4Rα-increased cell number in
both cell lines. Our results demonstrate that IL4R mediates enhanced glucose and glutamine metabolism in 4T1
cancer cells, and that IL4-induced growth is supported by IL4/IL4R-enhanced glutamine metabolism in both
human and murine mammary cancer cells. This highlights IL4Rα as a possible target for effective breast cancer
therapy.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Second only to skin cancer, breast cancer remains the most com-
monly diagnosed cancer in women in the United States [1]. Cytokines
and chemokines in the tumormicroenvironment promote breast cancer
progression and metastasis [2]. Interleukin-4 (IL4) is a Th2 immune
cytokine that binds and activates the type 1 IL4R on lymphoid cells
(composed of the IL4Rα and common gamma C chains) to promote
proliferation and survival [3]. Normal epithelial tissues typically do not
express IL4R, yet many epithelial cancers including breast cancer, up-
regulate a second type of IL4R, called the type II IL4R, which consists
of the IL4Rα and IL13Ra1 chains [4]. Notably, interleukin-13 (IL13)
can also activate the type II IL4R. However, IL4 is the prototypical IL4R
ligand, it binds with higher afﬁnity [5], and is upregulated in the breast
tumor microenvironment in patients [6].pported by R01 CA157781 (to
olecular Sciences training pro-
39).
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ingleton).Using two immune competent murine tumor models, we have de-
ﬁned IL4Rα expression in mammary cancer cells as a strong promoter
of metastatic tumor growth mediating enhanced proliferation and
survival [7]. Increased glucose consumption and utilization in activated
lymphocytes support these same pro-growth phenotypes [8,9]. Speciﬁ-
cally, IL4 induces T cell proliferation [10], and IL4/IL4Rα-induced glu-
cose metabolism is necessary to support the enhanced survival of B
cells [8,11]. However, there is no data regarding whether IL4/IL4Rα-
induced glucose metabolism serves as a novel mechanism to support
tumor growth. Normally, cells use glycolysis to metabolize glucose to
pyruvate, which is fed into the tricarboxylic acid (TCA) cycle and used
to generate ATP through oxidative phosphorylation. Highly proliferative
cells, including activated lymphocytes and cancer cells, induce a com-
paratively high rate of aerobic glycolysis and metabolize the majority
of glucose to lactate even when oxygen is present [12]. This phenome-
non, termed the “Warburg effect” in cancer, is often accompanied by
elevated glucose transporter (GLUT) expression to facilitate increased
glucose uptake, as generation of ATP per glucosemolecule from aerobic
glycolysis is relatively inefﬁcient. Enhanced aerobic glycolysis in tumors
is often indicated by increased extracellular lactate production as it cor-
relates proportionally with intracellular glycolytic activity [13]. The
reprogrammingofmetabolism is now considered anemerginghallmark
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ing periods of stress and proliferation [14]. How cancer cells achieve
such metabolic reprogramming is now an area of intense investigation.
There are 14 GLUT family members expressed in humans, of which
GLUT1 is the most extensively studied in cancer for mediating upregu-
lated glucose uptake and metabolism. Elevated expression of GLUT1
has been shown inmany epithelial cancer types including breast cancer
[15–18]. Importantly, IL4 signaling through the type I IL4R in B lympho-
cytes leads to increased expression of GLUT1 and other genes encoding
glycolytic enzymes [19], and GLUT1 expression has been associated
with IL4-increased glucose uptake [8].
In the setting of aerobic glycolysis, both activated lymphocytes and
cancer cells often also upregulate glutamine uptake and metabolism
to maintain the TCA cycle [9,20], and to provide purines and pyrimi-
dines for DNA and RNA synthesis [21].While colon and lung cancers de-
pend on enhanced glutaminemetabolism for survival and proliferation,
little is known about glutamine metabolism in breast cancer cells [22,
23]. Enhanced glutamine uptake may occur through increased ASC
amino-acid transporter 2 (ASCT2) expression, the major cancer-
related glutamine transporter [24,25]. Indeed, ASCT2 is expressed by a
variety of breast cancer subtypes including human luminal A, luminal
B, HER2 positive, and triple negative [26].
We have previously demonstrated that a traditionally immune
signaling axis, IL4/IL4Rα, is a direct promoter of two cancer-acquired
phenotypes in mammary cancer cells, survival and proliferation. Here,
we investigate whether IL4 can also enhance glucose and/or glutamine
metabolism in breast cancer cells expressing IL4Ra to support enhanced
tumor growth.
2. Materials and methods
2.1. Cell lines and culture
The MDA-MB-231 human breast cancer cell line, acquired from the
American Type Culture Collection (ATCC), was transfected with
SureSilencing™ small hairpin RNA (shRNA) plasmids directed toward
three different regions of human IL4Rα (NM_000418) or with control
non-target plasmids (SABiosciences) using Lipofectamine™ (Invitrogen).
Individual sh-control and IL4Rα knockdown clones were selected by
limiting dilution in 400 μg/mL hygromycin (Invitrogen). Immunoblot-
ting followed by densitometry analysis in Adobe Photoshop® was
used to calculate the percent of IL4Rα protein knockdown. The sources
for PyVT-R221a (R221a) and 4T1 cells, and the validation of shRNA-
mediated knockdown of IL4Rα in these murine mammary cancer cell
lines were previously described [7]. Cells were maintained at 37°C
with 5% CO2 in Dulbecco's modiﬁed Eagle's medium (DMEM, Corning)
containing 10% fetal bovine serum (FBS, Atlanta Biologicals), and the
appropriate selection agent. DMEM containing 2% FBS was used in all
experimental assays shown.
2.2. Western blot analysis
Whole cell lysates collected with radioimmunoprecipitation assay
(RIPA) lysis buffer containing protease inhibitors (Roche Applied Sci-
ence), and sonicated as necessary, were used for western blots. Lysates
used for GLUT1 blots were also deglycosylated by treatment with
PNGase F (New England Biolabs). Primary antibodies were obtained
from Santa Cruz Biotechnologies (human and murine IL4Rα, and
murine ASCT2), Millipore (Human ASCT2), Abcam (GLUT1), or Cell
Signaling (β-actin) and immunoblotting performed as previously de-
scribed [7].
2.3. Murine tumor models
All animal procedures were conducted in accordance with Guide-
lines for the Care and Use of Laboratory Animals following approval bythe Institutional Animal Care and Use Committee. Age-matched female
BALB/c and FVB/Nmice (Jackson Laboratories) were used for orthotopic
injections into the 4th mammary gland (2.5 × 105 4T1 cells per BALB/c
mouse or 2.5 × 105 R221a cells per FVB mouse). Prior to injection, indi-
vidual clones for each cell line (R221a or 4T1) were harvested and com-
bined to generate combined sh-control or IL4Rα KD samples. The time
to initial mammary tumor palpationwas documented as tumor latency.
Weekly caliper measurements were used to calculate tumor volume for
growth rates.Micewere sacriﬁcedwhen tumors reached 1 cm in any di-
mension. 4T1 injectionswere repeatedwith 2.5 × 105 cells for 6 days. At
necropsy, these mammary tumors were formalin-ﬁxed, parafﬁn-
embedded, and sectioned for immunohistochemical analysis. In a sepa-
rate study, R221a and 4T1 sh-control and IL4Rα knockdown cells were
labeledwith cell tracker red (Life Technologies) for 1 h prior to injection.
These mice were sacriﬁced 48 h post-injection and mammary glands
were homogenized and analyzed by ﬂow cytometry to assess the initial
seeding ability of tumor cells.
2.4. Immunohistochemical analysis of tissue sections
Tissue sections of 4T1 orthotopic tumors or archival 4T1 lungmetas-
tases were stained by immunohistochemistry using citrate antigen re-
trieval, and primary antibodies, GLUT1 (Abcam) against Ki67 (Abcam),
or cleaved caspase-3 (Cell Signaling Technology) as previously de-
scribed [7]. At least three separate orthotopic tumor areas and four sep-
arate metastatic lung tumors per mouse were imaged at 20× objective
magniﬁcation where 372 pixels is equivalent to 100 μm. The positively
stained area per tumor pixel area was measured by thresholding using
Metamorph® software.
2.5. Analysis of glucose and glutamine metabolism
Direct glucose uptake was measured using a glucose uptake cell-
based kit (Cayman Chemical). 4T1 parental cells were seeded in 2%
FBS DMEM (250,000 cells/well in 12-well plates). Post-attachment the
media was replaced with 2% FBS DMEM with recombinant murine IL4
(BD Biosciences) or 0.1% BSA in PBS (BSA-PBS) as a vehicle control,
and cells were allowed to grow for 22 h. Media was removed and
replaced with glucose-free and serum-free DMEM ±100 μg/mL 2-(N-
(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG)
and ±10 ng/mL IL4 or vehicle control for 2 h. 2-NBDG positive cells
were detected by ﬂow cytometry. In long-term metabolism assays,
cells (4T1 200,000 cells/plate or MDA-MB-231: 300,000 cells/plate for
4 days, or 500,000 cells/plate for 3 days) were seeded in 10 cm2 plates
in DMEM containing 2% FBS. Post-attachment, human or murine IL4
diluted in BSA-PBS or the BSA-PBS vehicle control was added to each
plate. IL4 or BSA-PBS was added to existing media every other day for
the duration of each study. At each timepoint, media was collected
from the plates, spun at 1000 rpm for 5 min, aliquoted, and frozen at
−80 °C before being thawed, diluted, and analyzed for metabolites.
Glucose consumption, glutamine consumption, and L-lactate produc-
tion were measured using commercial kits per the manufacturer's col-
orimetric protocol (glucose and glutamine kits from BioAssay Systems
and L-lactate kit from Cayman Chemical). The metabolite consumption
and production values from the media were normalized to the corre-
sponding total amount of protein in each plate as determined by
bicinchoninic acid (BCA, Thermo Scientiﬁc) assay of cell lysates. Lysates
collected were also analyzed by western blot for GLUT1 and ASCT2
expression. RNA was extracted from a separate set of plates using
QuickRNA Mini-prep (Zymo Research), and real time RT-PCR was per-
formed using custom primers (Invitrogen) against human and murine
GLUT1 and ASCT2 (primer sequences and sources are provided in Sup-
plementary Table 1). TheΔΔCTmethodwas used to quantify changes in
gene expression normalized to the expression of the human or murine
ribosomal 18S subunit.
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The glycolysis inhibitor, 2 Deoxy-D-glucose (2DG, Acros Organics),
was dissolved in sterile water, and the glutaminase inhibitor, 968
(Calbiochem), was dissolved in DMSO. The compounds were then
diluted in DMEM with 2% FBS for each experiment. Cell number in
response to IL4 in the presence or absence of 2DG or 968was quantiﬁed
using a CyQUANT® proliferation assay (Life Technologies), per the
manufacturer's protocol. In all CyQUANT® assays, cells were seeded
(4T1: 10,000 cells/well, MDA-MB-231: 8000 cells/well, in 48-well
plates) in 2% FBS DMEM, and allowed to attach before the media was
removed and replaced with 2% FBS DMEM containing IL4 (BD Biosci-
ences), the appropriate drug treatment, or vehicle control. Cells were
allowed to grow for 48 h in the presence of treatment prior to cell
number analysis.
2.7. EdU proliferation assays
4T1 cells or MDA-MB-231 cells were seeded in 8-well chamber
slides (10,000 cells/well) in DMEM containing 2% FBS. After attachment,
media was replaced with 2% FBS DMEMwith IL4 or PBS vehicle control,
and cells were allowed to proliferate for 46 h. 10 μM EdU (Invitrogen)
was added for the remaining 2 h of the 48 h studies. Cells were washed,
ﬁxed with 10% buffered formalin, and cells incorporating EdU (cells in S
phase) were labeled by Alexa Fluor® azide dye (594 nm or 488 nm
wavelength, Invitrogen) with 10 mM copper in a .5 M ascorbic acid
and 1.5 M Tris–HCL (pH 8.5) aqueous solution. Hoechst 33258 was
used to stain cell nuclei. Slideswere imaged at 20× objectivemagniﬁca-
tion, with three images taken perwell, and fourwells per condition. The
number of azide dye and Hoechst positive cells were quantiﬁed after
thresholding in ImageJ software, and used to calculate the percent of
cells in S phase for each image.
2.8. Recombinant IL4
Each batch of recombinant human and murine IL4 obtained from
BD Biosciences was tested for maximum effective dose using the
CyQUANT® assay described above for each cell line prior to use in ex-
periments since speciﬁc activity differed from lot to lot. In all experi-
ments, the dose of IL4 ranged from 10 to 20 ng/mL depending on its
measured mitogenic activity.
2.9. Statistical analysis
GraphPad Prism® software was used to perform all statistical analy-
ses. ANOVA or Kruskal–Wallis with post-testwas usedwhen comparing
more than two conditions. Otherwise, the parametric unpaired
Student's t test, or the nonparametric Mann–Whitney test was used.
In graphs, error bars represent the standard deviation, and P values
are represented by stars where: *≤ .05, **≤ .01, and ***≤ .001.
3. Results
3.1. IL4Rα promotes mammary tumor growth at the primary site
Having already established that IL4Rα is a strong promoter of meta-
static mammary tumor growth in the lung and liver [7], we then asked
whether IL4Rα expression can affect mammary tumor latency and
growth at the primary tumor site. For these studies, we used orthotopic
injection models with R221a and 4T1 sh-control or IL4Rα knockdown
cells. In contrast to the large tumors formed by sh-control cells, FVB
mice receiving R221a IL4Rα knockdown cells never formed palpable tu-
mors (Fig. 1A). Mice receiving sh-control 4T1 cells developed tumors on
average 4 days earlier than mice receiving IL4Rα knockdown 4T1 cells,although this difference in latency did not reach signiﬁcance (Fig. 1A).
For both the 4T1 and R221A cell lines, there was a signiﬁcant reduction
in IL4Rα knockdown tumor size at endpoint (Fig. S1A). Analysis by ﬂow
cytometry showed no difference in the number of labeled sh-control
or IL4Rα knockdown R221a or 4T1 cells in the mammary glands 48 h
post-injection (Fig. S1B). This indicates that disparities in R221a tumor
latency and R221a and 4T1 IL4Rα knockdown tumor size at endpoint
were not due to fewer IL4Rα knockdown cells surviving the initial
injection.
The growth rates of mammary tumors originating from IL4Rα
knockdown clones were signiﬁcantly reduced compared to sh-control
tumors for both cell lines (Fig. 1B). Immunohistochemistry for Ki67
and caspase-3 was then performed on 4T1 sh-control and IL4Rα knock-
downmammary tumors to assess whether IL4Rα-induced proliferation
or survival could contribute to enhanced mammary tumor growth.
There was a signiﬁcant difference in Ki67 positivity between control
and IL4Rα knockdown tumors (Fig. 1C), but no difference in caspase-3
positivity (Fig. 1D). Collectively, these data demonstrate that IL4Rα ex-
pression promotes mammary tumor proliferation leading to enhanced
growth at the primary tumor site.3.2. IL4 induces glucose uptake in mammary cancer cells
IL4 stimulation results in the activation of Akt in both 4T1 and R221a
cells [7], and PI3K/Akt signaling can elicit the translocation of glucose
transporters to the cell surface, thus increasing glucose uptake and the
corresponding lactate production [27–29]. We therefore directly mea-
sured glucose uptake as 2-NBDG uptake by ﬂow cytometry in 4T1 pa-
rental cells following 24 h of IL4 exposure. Glucose uptake reported as
mean 2-NBDG ﬂuorescence was signiﬁcantly increased in cells treated
with IL4 (Fig. 2A, B). Furthermore, using a sensitive multianalyte
microphysiometer (MAMP) [30,31], we found that IL4 stimulated lac-
tate production by ~8.5% from 4T1 cells within minutes of exposure
(data not shown). These data conﬁrmed that IL4 enhances short-term
glucose uptake and possibly its metabolism in mammary cancer cells.
However, tumor cells in themicroenvironmentwould likely be exposed
to stromally derived IL4 for longer periods of time. The question thus
remained whether IL4 could induce long-term changes in glucose and
glutamine metabolism to maintain enhanced tumor growth.
3.3. IL4Rαmediates enhanced GLUT1 expression in mammary cancer cells
IL4 treatment enhances the expression of GLUT1 and glucose uptake
in B cells [8,19]. GLUT1 has also been identiﬁed as the most highly
expressed GLUT isoform out of 12 GLUTs examined in several murine
mammary cancer cell lines, including 4T1 cells [32]. As an initial screen
for long-term changes in glucose metabolism in response to IL4, we ex-
amined changes in GLUT1 expression by western blot in 4T1 cells treat-
ed with IL4 every other day for a period of 8 days. Increased GLUT1
protein expression in response to IL4 was apparent by western blot by
day 8 (Fig. 3A). We further conﬁrmed IL4-induced expression of
GLUT1 by RT-PCR in 4T1 cells compared to untreated controls (Fig. 3B).
To verify that IL4Rαmediates GLUT1 upregulation, and to demon-
strate the in vivo relevance of our ﬁndings, we examined GLUT1 protein
expression by immunohistochemistry (IHC) in orthotopic 4T1mamma-
ry tumors. As expected, GLUT1 protein levels were reduced in IL4Rα
knockdown tumors compared to sh-control (Figs. 3C and S2A). We
then examined whether GLUT1 expression was dependent on IL4 by
performing IHC on archival metastatic 4T1 lung tumors established in
wildtype (WT) or IL4-null (IL4 KO) mice. As expected, loss of IL4Rα in
4T1 tumor cells injected into WT mice resulted in the reduced expres-
sion of GLUT1 in lung metastases (Figs. 3D and S2B). However, while
GLUT1 levels were reduced, they were not signiﬁcantly decreased in
lung tumors of IL4 KO mice compared to WT mice receiving sh-
control cells (Figs. 3D and S2B). These results suggest that IL4Rα
Fig. 1. IL4Rα promotes the growth of mammary tumors at the primary site. R221a or 4T1 sh-control (Ctl) or IL4Rα knockdown (KD) cells were orthotopically injected into the 4th mam-
mary gland ofmice. A)Representation of tumor latency for R221a (left, P b .0001) and 4T1 (right, P=NS)mammary tumors (R221an=16; 4T1 n=14). B)Graphsof R221a (left) and 4T1
(right) mammary tumor volume over time calculated from tumor dimensions (R221a n= 16; 4T1 n= 14). C) Quantiﬁcation of total Ki67 D) or cleaved caspase-3 positive area per 4T1
IL4Rα KD or sh-control mammary tumor area (n= 11). Murine tumor growth data represented in panels A and B was repeated with similar results obtained.
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sites in vivo, but indicate that in addition to IL4, there may also be a role
for the second IL4Rα-binding cytokine, IL13, in promoting GLUT1 ex-
pression through IL4Rα.Fig. 2. Glucose uptake inmammary cancer cells is increased following short-term IL4 exposure.
exposure to 2-NBDG±10 ng/mL IL4, and immediate analysis by ﬂow cytometry. A) Flow cytom
B) Quantiﬁcation of mean ﬂuorescence intensity by ﬂow cytometry representative of 2-NBDG3.4. IL4 enhances glucose metabolism long-term in mammary cancer cells
We next assessed long-term functional changes in glucose metabo-
lism in response to IL4/IL4Rα in 4T1 cells. IL4 was added to 4T1 cells4T1 parental cells were treatedwith vehicle or 10 ng/mLmurine IL4 for 22 h prior to a 2 h
etry trace of 2-NBDG uptake in 4T1 cells treatedwith IL4 (black) or vehicle control (gray).
uptake in 4T1 cells with IL4 or vehicle control.
Fig. 3. IL4Rαmediates enhanced expression of GLUT1 in mammary cancer cells. 4T1 sh-control clones were treated with vehicle or 20 ng/mL murine IL4 every other day for 8 days.
A) Western blot analysis of deglycosylated glucose transporter 1 (GLUT1) upregulation in 4T1 sh-control clones over time. B) Quantiﬁcation of GLUT1 mRNA expression normalized to
murine ribosomal S18 in 4T1 sh-control clones 6 days after initial IL4 treatment. Quantiﬁcation of IHC staining for GLUT1 in C) 4T1 sh-control (Ctl) and IL4Rα knockdown (KD) orthotopic
mammary tumors (n=8) and D) inmetastatic lung tumors originating from sh-control (Ctl) or IL4Rα knockdown (IL4Ra KD) 4T1 cells in wild-type (WT) or IL4 knockout (IL4 KO) mice
(n= 3–6). The upregulation of GLUT1 expression in response to IL4 was reproducible in three independent experiments, and IHC analysis of GLUT1 in 4T1 mammary tumors in two
separate experiments.
1223K.T. Venmar et al. / Biochimica et Biophysica Acta 1853 (2015) 1219–1228every other day for 8 days, and samples of growthmedia were collected
and analyzed for glucose and lactate levels. Both glucose consumption
(Fig. 4A) and lactate production (Fig. 4B) signiﬁcantly increased in
response to IL4 over time. In addition, a comparison between glucose
consumption (Fig. 4C) and lactate production (Fig. 4D) from 4T1 sh-
control and IL4Rα knockdown clones treated with IL4 for 6 days con-
ﬁrmed that IL4Rα mediates IL4-induced glucose metabolism. These
data conﬁrm that IL4/IL4Rα increases glucose metabolism over extend-
ed periods of time in mammary cancer cells.3.5. IL4 treatment results in long-term increases in glutamine metabolism
in breast cancer cells
Given our results with murine 4T1 mammary cancer cells, we next
sought to determine whether IL4/IL4Rα could induce changes in glu-
cose metabolism in human breast cancer cells using the MDA-MB-231
cell line. We ﬁrst established that IL4 could induce growth in MDA-
MB-231 cells, as it does in 4T1 cells (Fig. S3). As before, we performed
western blot analysis of GLUT1 protein expression in response to IL4
in MDA-MB-231 cells over a period of 8 days. Unlike 4T1 cells, MDA-
MB-231 cells at similar seeding densities began to lose viability after
day 4, which prompted us to look at earlier timepoints. At no point dur-
ing the 4 day study did IL4 induce GLUT1 protein expression in MDA-
MB-231 cells (Fig. 5A). GLUT1 expression actually decreased over time
in an IL4-independentmanner, possibly in response to depleted glucose
stores in the media over time. Furthermore, we saw no signiﬁcant in-
crease in glucose consumption when testing media from day 2, 3, or 4
(data not shown). We thus tested whether metabolism of the other
major carbon and nitrogen source, glutamine, could be regulated by
MDA-MB-231 cells.We performed western blot analysis for the expression of ASC-
amino acid transporter 2 (ASCT2, also known as SLC1A5), a major
cancer-related glutamine transporter [24,25], in response to IL4 in
MDA-MB-231 cells. ASCT2 protein levels increased within 24 h of IL4
exposure, and remained increased 2 days post exposure (Fig. 5B). We
then conﬁrmed the transcriptional upregulation of ASCT2 in response
to IL4 by RT-PCR (Fig. 5C). We next examined the ability of IL4 to en-
hance glutamine uptake over an extended period of time by culturing
MDA-MB-231 cells with IL4 and examining media glutamine levels
using an enzyme-based assay. IL4 increased glutamine uptake in
MDA-MB-231 cells approximately 2-fold (Fig. 5D).
To examine whether changes in glutamine metabolism in response
to IL4 are unique to the MDA-MB-231 cell line, we performed the
same analyses for ASCT2 expression and glutamine uptake with 4T1
cells. We conﬁrmed that IL4 was able to induce ASCT2 protein expres-
sion by western blot (Fig. 5E), and mRNA expression by RT-PCR
(Fig. 5F). In addition, IL4 treatment nearly tripled glutamine uptake in
4T1 cells following a 6 day exposure (Fig. 5G). Together, these results
indicate that long-term enhancement of glutamine metabolism by IL4
is a reproducible phenotype between human and murine breast cancer
cells.3.6. IL4-induced glutamine metabolism supports breast cancer growth
Having established that IL4 is capable of enhancing glucose and glu-
taminemetabolism in breast cancer cells, we thenwanted to determine
whether these processes are necessary to support IL4/IL4Rα-induced
tumor growth. sh-RNA mediated knockdown of IL4Rα in MDA-MB-
231 cells was performed to examine IL4/IL4R-mediated changes in
human breast cancer. Western blot analysis conﬁrmed a reduction
Fig. 4. IL4Rαmediates enhanced glucose metabolism long-term inmammary cancer cells. A) Glucose consumption (P b .0001) and B) lactate production (P b .0001) from 4T1 sh-control
cells treatedwith vehicle or 20 ng/mL IL4 every other day for 8 days. C) Comparison of glucose consumption andD) lactate production from4T1 sh-control (Ctl) or IL4Rα knockdown (KD)
clones 6 days after initial IL4 treatment. Glucose consumption and lactate productionweremeasured using enzyme based assays and normalized to total cellular protein contentmeasured
by BCA assay. Increased glucose uptake and lactate production in response to IL4 using the enzymatic assays was conﬁrmed in three independent experiments.
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down clones compared to sh-controls (Fig. 6A).
The glucose analog, 2 Deoxy-D-glucose (2DG), is commonly used to
inhibit glycolysis by blocking the initial rate-limiting step mediated by
the hexokinase 2 enzyme [33]. We determined the effective dose of
drug that inhibited 4T1 (Fig. S4A) and MDA-MB-231 (Fig. S4B) growth
in vitro by ﬁnding the dose that reduced cell number by ~50% (ED50)
in CyQUANT® assays. We then examined the ability of the ED50 dose
of 2DG to block IL4-induced growth in 4T1 and MDA-MB-231 sh-
control and IL4Rα knockdown cells by again quantifying changes in
cell number. As expected, IL4 treatment resulted in an increase in sh-
control cell number for both cell lines, and this responsewas attenuated
in IL4Rα knockdown cells (Fig. 6B, C). This pattern was true for each of
our cell number analyses (Fig. 6B–E).
In neither cell line did the inhibition of glycolysiswith 2DG attenuate
the percent increase in IL4-induced cell number compared with vehicle
control. This was true even though the increase in cell number between
2DG alone and IL4+2DG forMDA-MB-231 sh-control cells was not sta-
tistically signiﬁcant. These experiments were done 3 times for each cell
line and an average percent increase in cell number due to IL4 treatment
in the presence or absence of 2DGwas calculated. In 4T1 sh-control cells
without 2DG, IL4 treatment increased cell number by 21.7% compared
with vehicle. This was not statistically different from the 18.3% increase
in cell number induced by IL4 in the presence of 2DG. Similarly, inMDA-
MB-231 sh-control cellswithout 2DG, IL4 treatment increased cell num-
ber by 10.2% compared with vehicle, which was not statistically differ-
ent from the 10.7 % increase in cell number with IL4 in the presence of
2DG. This suggests that IL4 can induce breast cancer growth indepen-
dently of enhanced glucose uptake.
In a separate dose response assay, we determined the ED50 of com-
pound 968, an inhibitor of glutaminase 1 frequently used to block gluta-
mine metabolism [34], to inhibit growth in both cell lines (Fig. S4C, D),
before combining this dose with IL4. In both 4T1 (Fig. 6D) and MDA-
MB-231 cells (Fig. 6E), the ED50 of 968 signiﬁcantly blocked IL4-
increased cell number. Again, these experiments were done 3 timesfor each cell line. In 4T1 sh-control cells, IL4 treatment increased cell
number by 16% compared with vehicle. However, the increase was
signiﬁcantly attenuated to only 1.2% (P = 0.02) when the assay was
repeated in the presence of 968. Similarly, in MDA-MB-231 sh-control
cells, IL4 treatment increased cell number by 11.5% compared with ve-
hicle, which was signiﬁcantly different (P= 0.04) to the 5.6% increase
seen in the presence of 968. Collectively, our data demonstrates that
glutaminemetabolism, but not glucosemetabolism, is necessary to sup-
port IL4-induced growth of breast cancer cells in vitro. Interestingly, the
combined treatment of 4T1 cells (Fig. 6F) and MDA-MB-231 cells
(Fig. 6G) with the ED50 of 2DG and 968 showed an additive effect in
blocking growth compared to either drug alone.
Using EdU incorporation assays to measure proliferation as the per-
cent of cells in S phase, we were able to demonstrate that IL4 treatment
results in an increase in proliferation in both 4T1 (Fig. S5A) and MDA-
MB-231 (Fig. S5B) cells in a dose dependent manner. Using sh-control
and IL4Rα knockdown cell in similar assays, we conﬁrmed that IL4Rα
mediates this increase in proliferation in response to IL4 in both cell
lines (Fig. S5C, D). These data support the association between IL4Rα
expression and enhanced proliferation in 4T1 mammary tumors
in vivo, and indicate that IL4-induced proliferation could contribute to
IL4-induced growth in vitro.
4. Discussion
The Th2 immune cytokine, interluekin-4 (IL4), is known to induce
lymphocyte activation and differentiation, and regulate increased lym-
phocyte proliferation and survival through the type I IL4 receptor
(IL4R) [3].We previously deﬁned a novel role for IL4 in directly promot-
ing the proliferation and survival of mammary cancer cells expressing
type II IL4Rs for enhanced growth at metastatic lung and liver sites [7].
Here, we used two orthotopic models of murine mammary cancer
with R221a or 4T1 IL4Rα knockdown or sh-control clones, to demon-
strate that expression of IL4Rα, a component of IL4Rs, also promotes
mammary tumor growth at the primary site. Strikingly, shRNA-
Fig. 5. IL4 induces the expression of glutamine transporters and long-term glutamine uptake in breast cancer cells. MDA-MB-231 parental cells were treated with vehicle or 10 ng/mL
human IL4 every other day for 4 days. A) Western blot analysis of deglycosylated glucose transporter 1 (GLUT1) protein expression in MDA-MB-231 cells in response to IL4 over time.
B) Western blot analysis of glutamine transporter ASC-amino acid transporter 2 (ASCT2) upregulation in MDA-MB-231 cells in response to IL4. C) Quantiﬁcation of mRNA expression
of ASCT2 normalized to ribosomal S18 in MDA-MB-231 cells treated with vehicle or 10 ng/mL IL4 for 24 h. D) Quantiﬁcation of glutamine consumption in MDA-MB-231 cells 3 days
after initial IL4 exposure compared to a vehicle treated control. 4T1 sh-control cloneswere treatedwith vehicle or 20 ng/mLmurine IL4 every other day for 6 days. E)Western blot analysis
of ASCT2 upregulation in 4T1 cells. F) Quantiﬁcation of mRNA expression of ASCT2 normalized to ribosomal S18 in 4T1 cells treated with vehicle or 20 ng/mL IL4 for 2 days.
G) Quantiﬁcation of glutamine consumption 6 days after initial IL4 exposure compared to a vehicle treated control. Glutamine consumption was measured using an enzyme-based
assay and normalized to total cellular protein content by BCA assay. Upregulation of ASCT2 protein in response to IL4was conﬁrmed in two independent experiments, and the upregulation
of glutamine metabolism in each cell line was reproducible in three independent experiments per cell line.
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mammary tumor take and growth. This result prevented further analy-
sis of knockdown tumors, as there were none at endpoint. While this
stark result was not achieved with 4T1 IL4Rα knockdown clones,
there was a reduction in average tumor latency, and a signiﬁcant reduc-
tion in the rate of tumor growth compared to 4T1 sh-control clones. Dis-
parities in latency between the 4T1 versus R221a cell lines may be
attributable to themore aggressive nature of the 4T1 cell line, discussed
previously [7].Immunohistochemical analysis of 4T1 mammary tumors by Ki67 or
caspase-3 staining at endpoint demonstrated that increased prolifera-
tion but not survival contributed to IL4Rα-enhanced mammary tumor
growth. This result is in accordance with our previous study showing
that IL4Rα-enhanced proliferation rather than survival promotes the
growth of allografted colon tumors in the cecum [35]. Given that
IL4Rα expression consistently mediated enhanced tumor growth in all
of our primary andmetastaticmammary tumormodels,we then sought
to determine whether IL4/IL4Rα-induced metabolism could serve as a
Fig. 6. Increased breast cancer growth in response to IL4/IL4Rα is dependent upon glutamine but not glucose metabolism in vitro. A)Western blot analysis illustrating the percent knock-
down of IL4Rα protein expression inMDA-MB-231 cells.MDA-MB-231 or 4T1 sh-control (Ctl) or IL4Rα knockdown (IL4RαKD) cloneswere cultured±IL4 (MDA-MB-231 cells: 10 ng/mL
human IL4; 4T1 cells: 20 ng/mLmurine IL4) and±metabolic inhibitors for 48 h before cell number was analyzed using a CyQUANT® proliferation kit and standard curves. Graphs in B–E
represent data from individual experiments, and each of these experiments was repeated twice more with similar results obtained. Treatment with the glycolysis inhibitor, 2DG, did not
inhibit IL4-induced increases in cell number in B) 4T1 clones (±1.5 mM 2DG) or C) MDA-MB-231 clones (±12mM 2DG). Treatment with the glutaminase 1 inhibitor, 968, blocked IL4-
induced increases in cell number in both D) 4T1 clones (±10 μM968) and E)MDA-MB-231 clones (±20 μM 968). F) The combined treatment of both 4T1 cells (1.5 mM 2DG and 10 μM
968) and G) MDA-MB-231 cells (12 mM 2DG and 15 μM 968) with 2DG and 968 had an additive effect in reducing cell number compared to either drug or vehicle alone. Experiments
represented in F–G were repeated with similar results obtained.
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was based on previous reports of IL4-mediated metabolic changes in
lymphocytes [8,11].
We show that elevated glucose transporter 1 (GLUT1) expression is
associated with long-term increases in glucose metabolism (increased
glucose uptake and lactate production) downstream of IL4/IL4Rα in
murine mammary cancer cells. Elevated GLUT1 expression was also as-
sociated with IL4Rα expression in primary and metastatic 4T1 tumors
in vivo. Interestingly, total protein levels of GLUT1 were not evidentlyincreased until day 8 of IL4 treatment with 4T1 cells in vitro, while sig-
niﬁcant increases in glucose metabolism were evident by day 6 in the
same study. This indicates that IL4/IL4Rα signaling may also inﬂuence
the translocation of GLUT1 to the membrane for more immediate
increases in glucose uptake andmetabolism in addition to the later tran-
scriptional upregulation of GLUT1 for maintaining enhanced glucose
metabolism long-term. This concept is supported by additional experi-
ments demonstrating increased glucose uptake by 2-NBDG uptake
assay, and increased lactate production detected by multianalyte
1227K.T. Venmar et al. / Biochimica et Biophysica Acta 1853 (2015) 1219–1228microphysiometry [30,31] (data not shown), after short-term IL4 expo-
sure. However, more detailed assessment of GLUT1 translocation is
required to substantiate this idea.
While other GLUT isoformshave been detected in breast cancer, only
the overexpression of GLUT1 has been associatedwith poorer prognosis
[15,36,37], and with increased [18F]-ﬂuoro-deoxyglucose (FDG) uptake
in human breast tumors [18]. However, we were unable to detect in-
creases in GLUT1 expression or glycolysis (data not shown) in response
to IL4 in the humanMDA-MB-231 breast cancer cell line. One main dif-
ference between these cells and 4T1 mammary cancer cells is their ex-
pression of oncogenic K-Ras, which is known to drive enhanced
glucose uptake and metabolism. In fact, metabolic ﬂux analysis of
MDA-MB-231 cells revealed a basal stoichiometric relationship be-
tween high glucose consumption and lactate production [38]. It is there-
fore feasible that IL4 treatmentwould have no added affect on glycolysis
in this cell line as nearly all glucose consumed is already being shunted
to lactate production. In addition, MDA-MB-231 cells required nearly 6
times the dose of glycolysis inhibitor, 2-Deoxy-D-glucose (2DG), to in-
hibit growth in vitro compared with 4T1 cells. MDA-MB-231 cells in
general may be less reliant upon glucose metabolism for growth, and
metabolism of glutamine as a carbon and nitrogen source during
growth may be of greater importance. Glutamine metabolism has
been shown to promote the viability and proliferation of MDA-MB-
231 cells [38].
Although classiﬁed as a non-essential amino acid, glutamine is taken
up disproportionally more by cancer cells than normal cells, and the
therapeutic targeting of glutamine addiction is being considered for
anti-cancer treatments [39]. ASC amino-acid transporter 2 (ASCT2), is
a major transporter upregulated by breast cancer cells for enhanced
glutamine uptake [24,25]. Here, we show that IL4 is a novel regulator
of elevated ASCT2mRNA and protein expression, and this was associat-
ed with enhanced long-term glutamine uptake in both 4T1 and MDA-
MB-231 cells. In addition, inhibition of glutamine metabolism with
compound 968 blocked IL4-induced growth in both cell lines. Although
there appears to be a general need for glutamine metabolism indepen-
dent of IL4 in breast cancer, our results provide evidence for a novel role
of IL4-enhanced glutamine metabolism in supporting IL4-induced
growth in both murine and human breast cancer cells.
Supporting the concept that enhanced glutamine metabolism may
be the predominantmetabolic phenotype backing breast cancer growth
in response to IL4, IL4-induced growthwas not attenuatedwhen glycol-
ysis was pharmacologically inhibited with 2DG treatment in either cell
line. This result was not unexpected in the MDA-MB-231 cell line as
IL4 did not induce glucose metabolism in these cells. While IL4 did en-
hance glucose metabolism in 4T1 cells, the inability of 2DG to block
IL4-induced growth in these cells does notmean that IL4-enhanced glu-
cose metabolism cannot support IL4-induced survival or proliferation
speciﬁcally. Wewere able to show that IL4/IL4Rα-induced proliferation
likely contributes to IL4Rα-induced growth in vitro, and similarly to B
cells, there may still be a role for IL4-enhanced glucose metabolism in
supporting survival for enhanced tumor growth, although this remains
to be explored. In addition, the combined treatment of both 4T1 cells
andMDA-MB-231 cells with 2DG and the glutamine metabolism inhib-
itor, compound 968, did have an additive effect in blocking growth
compared to either drug alone. These data could indicate a possible
compensatorymechanismwhere enhanced glutaminemetabolism sup-
ports biosynthetic processes during growthwhen glycolysis is inhibited.
Here, we have shown for theﬁrst time that an immune cytokine, IL4,
can reprogram glucose and glutaminemetabolism in breast cancer cells
expressing the type II IL4 receptor. Importantly, IL4-induced glutamine
metabolism supports IL4/IL4Rα-enhanced growth in both human and
mammary cancer cells. The beneﬁts of therapeutically targeting the
IL4/IL4Rα signaling axis may be three fold. We have already identiﬁed
this axis as a strong promoter of mammary cancer survival and prolifer-
ation, and this work highlights a third targetable hallmark of cancer in-
duced by IL4, IL4/IL4Rα-induced metabolism. Fortunately, therapiesspeciﬁcally targeting the type II IL4 receptor on epithelial cancer cells
are currently being developed [40].Transparency Document
The Transparency document associated with this article can be
found, in the online version.
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